Jonathan W Goldman

Title(s)HS Associate Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024 Mar 27. Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao CY, Mahipal A, Shergill A, Spira AI, Goldman JW, Scallan CD, Schenk D, Palmer CD, Davis MJ, Kounlavouth S, Kemp L, Yang A, Li YJ, Likes M, Shen A, Boucher GR, Egorova M, Veres RL, Espinosa JA, Jaroslavsky JR, Kraemer Tardif LD, Acrebuche L, Puccia C, Sousa L, Zhou R, Bae K, Hecht JR, Carbone DP, Johnson B, Allen A, Ferguson AR, Jooss K. PMID: 38538867.
      View in: PubMed   Mentions:    Fields:    
    2. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. Target Oncol. 2024 Mar 11. Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Bonanno L, Dómine M, Poole L, Bolanos A, Rukazenkov Y, Wu YL. PMID: 38466534.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden. Psychosom Med. 2024 Feb 27. Williamson TJ, Garon EB, Irwin MR, Choi AK, Goldman JW, Stanton AL. PMID: 38436657.
      View in: PubMed   Mentions:    Fields:    
    4. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835. Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, Trukhin D, Hochmair MJ, Özgüroglu M, Ji JH, Statsenko G, Conev N, Bondarenko I, Havel L, Losonczy G, Xie M, Lai Z, Godin-Heymann N, Mann H, Jiang H, Shrestha Y, Goldman JW. PMID: 37801329; PMCID: PMC10870117.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    5. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol. 2024 Feb 15. Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. PMID: 38357801.
      View in: PubMed   Mentions:    Fields:    
    6. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jan 11. Wu TC, Luterstein E, Neilsen BK, Goldman JW, Garon EB, Lee JM, Felix C, Cao M, Tenn SE, Low DA, Kupelian PA, Steinberg ML, Lee P. PMID: 38206614; PMCID: PMC10784998.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30; 389(22):2039-2051. Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N, PAPILLON Investigators. PMID: 37870976.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    8. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023 10; 34(10):885-898. Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. PMID: 37597578.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers. Clin Cancer Res. 2023 08 15; 29(16):2979-2987. Rotow J, Patel JD, Hanley MP, Yu H, Awad M, Goldman JW, Nechushtan H, Scheffler M, Kuo CS, Rajappa S, Harada G, Clifford S, Santucci A, Silva L, Tupper R, Oxnard GR, Kherani J, Drilon A. PMID: 36996322; PMCID: PMC10524391.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 07 20; 41(21):3700-3711. Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussain M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. PMID: 37270692.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    11. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13; 389(2):137-147. Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL, ADAURA Investigators. PMID: 37272535.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    12. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 09; 18(9):1209-1221. John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. PMID: 37236398.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    13. Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer. Front Oncol. 2023; 13:1178313. Goldman JW, Sholl LM, Dacic S, Fishbein MC, Murciano-Goroff YR, Rajaram R, Szymczak S, Szpurka AM, Chao BH, Drilon A. PMID: 37274265; PMCID: PMC10232990.
      View in: PubMed   Mentions:
    14. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. Clin Lung Cancer. 2023 06; 24(4):376-380. Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, Chen A, van der Gronde T, He J. PMID: 36872181.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. JTO Clin Res Rep. 2023 Mar; 4(3):100468. Smith CP, Xiang M, Yoon SM, Lee A, Ruan D, Goldman JW, Cummings AL, Lisberg A, Garon EB, Moghanaki D. PMID: 36923158; PMCID: PMC10009282.
      View in: PubMed   Mentions: 1  
    16. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J Immunother Cancer. 2023 02; 11(2). Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin JS, Zannori C, Vermaelen K, Arén Frontera O, Curioni Fontecedro A, Sánchez-Gastaldo A, Juan-Vidal O, Linardou H, Poddubskaya E, Spigel DR, Ahmed S, Maio M, Li S, Chang H, Fiore J, Acevedo A, Paz-Ares L. PMID: 36725084; PMCID: PMC9896179.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    17. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 04 01; 41(10):1830-1840. Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. PMID: 36720083; PMCID: PMC10082285.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    18. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Dec; 3(12):100427. Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. PMID: 36426286; PMCID: PMC9679033.
      View in: PubMed   Mentions: 5  
    19. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. PMID: 36288547; PMCID: PMC9928626.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    20. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 09 01; 28(17):3709-3719. Goldman JW, Piha-Paul SA, Curti B, Pedersen KS, Bauer TM, Groenland SL, Carvajal RD, Chhaya V, Kirby G, McGlinchey K, Hammond SA, Streicher K, Townsley DM, Chae YK, Voortman J, Marabelle A, Powderly J. PMID: 35699623.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    21. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer. Future Oncol. 2022 Sep; 18(28):3133-3141. Tsuboi M, Goldman JW, Wu YL, Johnson ML, Paz-Ares L, Yang JC, Besse B, Su W, Chao BH, Drilon A. PMID: 35950566.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    22. ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. Clin Cancer Res. 2022 06 13; 28(12):2517-2526. Johnson M, Dudek AZ, Sukari A, Call J, Kunk PR, Lewis K, Gainor JF, Sarantopoulos J, Lee P, Golden A, Harney A, Rothenberg SM, Zhang Y, Goldman JW. PMID: 35302585.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    23. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clin Cancer Res. 2022 06 01; 28(11):2286-2296. Majem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. PMID: 35012927; PMCID: PMC9359973.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    24. Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report. JTO Clin Res Rep. 2022 Jun; 3(6):100330. Chen Y, Paz-Ares L, Reinmuth N, Garassino MC, Statsenko G, Hochmair MJ, Özgüroglu M, Verderame F, Havel L, Losonczy G, Conev NV, Hotta K, Ji JH, Spencer S, Dalvi T, Jiang H, Goldman JW. PMID: 35719865; PMCID: PMC9204731.
      View in: PubMed   Mentions: 11  
    25. Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study. Health Psychol. 2022 Apr; 41(4):301-310. Williamson TJ, Garon EB, Shapiro JR, Chavira DA, Goldman JW, Stanton AL. PMID: 35324247; PMCID: PMC9030259.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. Clin Lung Cancer. 2022 06; 23(4):300-310. Camidge DR, Moran T, Demedts I, Grosch H, Mileham K, Molina J, Juan-Vidal O, Bepler G, Goldman JW, Park K, Wallin J, Wijayawardana SR, Wang XA, Wacheck V, Smit E. PMID: 35400584.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    27. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 04; 7(2):100408. Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW. PMID: 35279527; PMCID: PMC9161394.
      View in: PubMed   Mentions: 58  Translation:Humans
    28. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clin Res Rep. 2022 Jan; 3(1):100262. Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K. PMID: 35005654; PMCID: PMC8717236.
      View in: PubMed   Mentions: 3  
    29. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 12; 19(12):1441-1464. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. PMID: 34902832; PMCID: PMC10203822.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    30. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2022 03 01; 40(7):710-718. Le X, Cornelissen R, Garassino M, Clarke JM, Tchekmedyian N, Goldman JW, Leu SY, Bhat G, Lebel F, Heymach JV, Socinski MA. PMID: 34843401; PMCID: PMC8887939.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    31. Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncol Pract. 2022 04; 18(4):e484-e494. D'Ambruoso SF, Glaspy JA, Hurvitz SA, Wenger NS, Pietras C, Ahmed K, Drakaki A, Goldman JW, Anand S, Simon W, Kung J, Coscarelli A, Rosen LS, Peddi PF, Wong DJL, Santos K, Phung P, Karlin D, Walling AM. PMID: 34748398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol. 2022 03; 17(3):423-433. Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, Kato T, Laktionov K, Vu HV, Wang Z, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Atasoy A, Herbst RS, Tsuboi M. PMID: 34740861.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    33. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncol. 2021 Dec 01; 17(35):4827-4835. Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. PMID: 34723634.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Rev Anticancer Ther. 2021 10; 21(10):1105-1124. Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI. PMID: 34176404.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    35. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer. 2021 11; 161:34-41. Zhou N, Velez MA, Bachrach B, Gukasyan J, Fares CM, Cummings AL, Lind-Lebuffe JP, Akingbemi WO, Li DY, Brodrick PM, Yessuf NM, Rettinger S, Grogan T, Rochigneux P, Goldman JW, Garon EB, Lisberg A. PMID: 34507111; PMCID: PMC8923054.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    36. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792. Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. PMID: 34426443.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    37. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer. 2021 11; 22(6):601-606. Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW. PMID: 34389237; PMCID: PMC10470656.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    38. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 07 01; 27(13):3630-3640. Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Mishra V, Schröder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. PMID: 33820783.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    39. Combination treatment options for small-cell lung cancer - Authors' reply. Lancet Oncol. 2021 03; 22(3):e84. Goldman JW, Paz-Ares L. PMID: 33662292.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. Clin Transl Sci. 2021 03; 14(2):664-670. Goldman JW, Barve M, Patel JD, Wozniak A, Dowlati A, Starodub A, Owonikoko TK, Edenfield W, Laurie SA, Da Costa D, Lally S, Koch M, Kosloski MP, Hoffman D, Dy GK. PMID: 33340277; PMCID: PMC7993269.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    41. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 01; 22(1):51-65. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN investigators. PMID: 33285097.
      View in: PubMed   Mentions: 216     Fields:    Translation:HumansCTClinical Trials
    42. Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. Nat Cancer. 2020 12; 1(12):1167-1175. Cummings AL, Gukasyan J, Lu HY, Grogan T, Sunga G, Fares CM, Hornstein N, Zaretsky J, Carroll J, Bachrach B, Akingbemi WO, Li D, Noor Z, Lisberg A, Goldman JW, Elashoff D, Bui AAT, Ribas A, Dubinett SM, Rossetti M, Garon EB. PMID: 35121931.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    43. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. Front Oncol. 2020; 10:578756. Goldman JW, Mazieres J, Barlesi F, Dragnev KH, Koczywas M, Göskel T, Cortot AB, Girard N, Wesseler C, Bischoff H, Nadal E, Park K, Lu S, Taus A, Cobo M, Estrem ST, Wijayawardana SR, Turner K, Oakley GJ, Hurt KC, Chiang AY, Hossain AM, John WJ, Paz-Ares L. PMID: 33194700; PMCID: PMC7649422.
      View in: PubMed   Mentions: 28  
    44. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 10 29; 383(18):1711-1723. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS, ADAURA Investigators. PMID: 32955177.
      View in: PubMed   Mentions: 505     Fields:    Translation:HumansCTClinical Trials
    45. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020 11; 149:46-52. Goldman JW, Garassino MC, Chen Y, Özgüroglu M, Dvorkin M, Trukhin D, Statsenko G, Hotta K, Ji JH, Hochmair MJ, Voitko O, Havel L, Poltoratskiy A, Losonczy G, Reinmuth N, Patel N, Laud PJ, Shire N, Jiang H, Paz-Ares L. PMID: 32961445.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    46. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 08 27; 383(9):825-835. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. PMID: 32846061; PMCID: PMC10777663.
      View in: PubMed   Mentions: 215     Fields:    Translation:HumansCTClinical Trials
    47. Targeted Therapy for Non-Small Cell Lung Cancer. Semin Respir Crit Care Med. 2020 Jun; 41(3):409-434. Noor ZS, Cummings AL, Johnson MM, Spiegel ML, Goldman JW. PMID: 32450595.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    48. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2020 02 20; 38(6):538-547. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. PMID: 31809241; PMCID: PMC7030895.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCTClinical Trials
    49. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. Front Oncol. 2019; 9:1256. Goldman JW, Waterhouse DM, George B, O'Dwyer PJ, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, Kelly K. PMID: 31850192; PMCID: PMC6901975.
      View in: PubMed   Mentions: 5  
    50. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. PMID: 31732494; PMCID: PMC6954326.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansCTClinical Trials
    51. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 11 23; 394(10212):1929-1939. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW, CASPIAN investigators. PMID: 31590988.
      View in: PubMed   Mentions: 708     Fields:    Translation:HumansCTClinical Trials
    52. KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment. Transl Lung Cancer Res. 2019 Oct; 8(5):706-709. Cummings AL, Santoso KM, Goldman JW. PMID: 31737507; PMCID: PMC6835110.
      View in: PubMed   Mentions: 4  
    53. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019 10 01; 37(28):2518-2527. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. PMID: 31154919; PMCID: PMC6768611.
      View in: PubMed   Mentions: 461     Fields:    Translation:HumansCTClinical Trials
    54. Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. Lung Cancer. 2019 09; 135:104-109. Noor ZS, Goldman JW, Lawler WE, Telivala B, Braiteh F, DiCarlo BA, Kennedy K, Adams B, Wang X, Jones B, Slamon DJ, Garon EB. PMID: 31446981.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    55. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 08 15; 25(16):5061-5068. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. PMID: 31113840; PMCID: PMC6901027.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    56. Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story. J Thorac Oncol. 2019 02; 14(2):160-162. Goldman JW, Garon EB. PMID: 30683290.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    57. EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2018 Nov; 2:1-13. Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel SM, Reckamp KL, Camidge DR, Pérol M, Ou SI, Liu SV, Yu HA, Soria JC, Socinski MA, Mekhail TM, Solomon BJ, Natale RB, Otterson GA, Papadimitrakopoulou V, Langer CJ, Neal JW, Despain D, Yurasov S, Litten JB, Erlander M, Raponi M, Wakelee HA. PMID: 35135111.
      View in: PubMed   Mentions: 5     Fields:    
    58. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2018 10 01; 29(10):2143. Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J. PMID: 30060089.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    59. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report. BMC Nephrol. 2018 08 20; 19(1):210. Goldman JW, Abdalla B, Mendenhall MA, Sisk A, Hunt J, Danovitch GM, Lum EL. PMID: 30126374; PMCID: PMC6102916.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    60. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. Clin Cancer Res. 2018 11 15; 24(22):5543-5551. Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW. PMID: 30082474.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    61. nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Front Oncol. 2018; 8:262. Langer CJ, Kim ES, Anderson EC, Jotte RM, Modiano M, Haggstrom DE, Socoteanu MP, Smith DA, Dakhil C, Konduri K, Berry T, Ong TJ, Sanford A, Amiri K, Goldman JW, Weiss J, ABOUND.70+ Investigators. PMID: 30087851; PMCID: PMC6066531.
      View in: PubMed   Mentions: 5  
    62. A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. J Thorac Oncol. 2018 09; 13(9):1284-1293. Williamson TJ, Choi AK, Kim JC, Garon EB, Shapiro JR, Irwin MR, Goldman JW, Bornyazan K, Carroll JM, Stanton AL. PMID: 29981926; PMCID: PMC6291203.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    63. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018 08; 13(8):1138-1145. Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. PMID: 29874546; PMCID: PMC6063769.
      View in: PubMed   Mentions: 237     Fields:    Translation:HumansCTClinical Trials
    64. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. J Thorac Oncol. 2018 09; 13(9):1363-1372. Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N. PMID: 29802888.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    65. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2018 03 01; 29(3):700-706. Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J. PMID: 29216356; PMCID: PMC5889041.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCellsCTClinical Trials
    66. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep. 2018 02 07; 8(1):2592. Dhar M, Wong J, Che J, Matsumoto M, Grogan T, Elashoff D, Garon EB, Goldman JW, Sollier Christen E, Di Carlo D, Kulkarni RP. PMID: 29416054; PMCID: PMC5803213.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    67. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Cancer Immunol Res. 2018 03; 6(3):288-294. Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, Morris K, Linares P, Adame C, Spiegel ML, Wells C, McKenzie J, Ledezma B, Mendenhall M, Abarca P, Bornazyan K, Hunt J, Moghadam N, Chong N, Nameth D, Marx C, Madrigal J, Vangala S, Shaverdian N, Elashoff D, Garon EB. PMID: 29382669; PMCID: PMC6066474.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    68. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Ther Adv Med Oncol. 2018; 10:1758834017751634. Shen J, Chang J, Mendenhall M, Cherry G, Goldman JW, Kulkarni RP. PMID: 29383039; PMCID: PMC5784551.
      View in: PubMed   Mentions: 9  
    69. Are liquid biopsies a surrogate for tissue EGFR testing? Ann Oncol. 2018 01 01; 29(suppl_1):i38-i46. Goldman JW, Noor ZS, Remon J, Besse B, Rosenfeld N. PMID: 29462257.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    70. Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. Radiology. 2018 04; 287(1):326-332. Tsai EB, Pomykala K, Ruchalski K, Genshaft S, Abtin F, Gutierrez A, Kim HJ, Li A, Adame C, Jalalian A, Wolf B, Garon EB, Goldman JW, Suh R. PMID: 29232184; PMCID: PMC6276060.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    71. Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer. Invest New Drugs. 2018 08; 36(4):629-637. Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A. PMID: 29196957; PMCID: PMC6061137.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    72. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer. 2017 Dec 15; 123(24):4800-4807. Spiegel ML, Goldman JW, Wolf BR, Nameth DJ, Grogan TR, Lisberg AE, Wong DJL, Ledezma BA, Mendenhall MA, Genshaft SJ, Gutierrez AJ, Abtin F, Wallace WD, Adame CR, McKenzie JR, Abarca PA, Li AJ, Strunck JL, Famenini S, Carroll JM, Tucker DA, Sauer LM, Moghadam NM, Elashoff DA, Abaya CD, Brennan MB, Garon EB. PMID: 29125624; PMCID: PMC6263029.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    73. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017 11; 5(11):891-902. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. PMID: 29056570.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    74. Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2018 01; 19(1):e19-e28. Gaut D, Sim MS, Yue Y, Wolf BR, Abarca PA, Carroll JM, Goldman JW, Garon EB. PMID: 28712979; PMCID: PMC5761337.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    75. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 07; 18(7):895-903. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. PMID: 28551359; PMCID: PMC5538772.
      View in: PubMed   Mentions: 493     Fields:    Translation:HumansCTClinical Trials
    76. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res. 2017 Aug 15; 23(16):4556-4568. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. PMID: 28468947; PMCID: PMC5599263.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCellsCTClinical Trials
    77. Biophysical isolation and identification of circulating tumor cells. Lab Chip. 2017 04 11; 17(8):1452-1461. Che J, Yu V, Garon EB, Goldman JW, Di Carlo D. PMID: 28352869; PMCID: PMC5507599.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    78. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017 04 01; 28(4):874-881. Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA. PMID: 28168303; PMCID: PMC6354672.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCTClinical Trials
    79. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 03 21; 10(1):73. Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, Roeland EJ. PMID: 28327200; PMCID: PMC5361694.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    80. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 01; 18(1):31-41. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. PMID: 27932067; PMCID: PMC5476941.
      View in: PubMed   Mentions: 433     Fields:    Translation:HumansCTClinical Trials
    81. Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 11 14; 7:13513. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. PMID: 27841271; PMCID: PMC5114547.
      View in: PubMed   Mentions: 12     Fields:    
    82. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clin Cancer Res. 2017 04 15; 23(8):1910-1919. Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M. PMID: 27803065.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    83. Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. Oncologist. 2016 Nov; 21(11):1326-1336. Goldman JW, Mendenhall MA, Rettinger SR. PMID: 27473045; PMCID: PMC5189614.
      View in: PubMed   Mentions: 26     Fields:    
    84. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs. 2016 10; 34(5):604-13. Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI. PMID: 27424159; PMCID: PMC6863157.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    85. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 09 01; 34(25):2969-79. Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. PMID: 27354481; PMCID: PMC5569693.
      View in: PubMed   Mentions: 230     Fields:    Translation:HumansCTClinical Trials
    86. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 09 01; 34(25):2980-7. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD. PMID: 27354485; PMCID: PMC5569692.
      View in: PubMed   Mentions: 243     Fields:    Translation:HumansCTClinical Trials
    87. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 06 10; 7:11815. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. PMID: 27283993; PMCID: PMC4906406.
      View in: PubMed   Mentions: 296     Fields:    Translation:Humans
    88. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 2016 07; 6(7):740-53. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. PMID: 27217383.
      View in: PubMed   Mentions: 319     Fields:    Translation:HumansAnimals
    89. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs R D. 2016 Mar; 16(1):45-52. Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J. PMID: 26689566; PMCID: PMC4767718.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    90. Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol. 2016 Feb; 77(2):439. Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR. PMID: 26589791; PMCID: PMC4969883.
      View in: PubMed   Mentions:    Fields:    
    91. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clin Cancer Res. 2016 05 15; 22(10):2386-95. Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria JC, Solomon B, Camidge DR, Gadgeel S, Paweletz C, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee H. PMID: 26747242; PMCID: PMC6886231.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    92. High efficiency vortex trapping of circulating tumor cells. Biomicrofluidics. 2015 Nov; 9(6):064116. Dhar M, Wong J, Karimi A, Che J, Renier C, Matsumoto M, Triboulet M, Garon EB, Goldman JW, Rettig MB, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D. PMID: 26697126; PMCID: PMC4684572.
      View in: PubMed   Mentions: 18  
    93. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015 Nov; 76(5):925-32. Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR. PMID: 26370544; PMCID: PMC4612319.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    94. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. Clin Lung Cancer. 2016 Jan; 17(1):80-4. Goldman JW, Shi P, Reck M, Paz-Ares L, Koustenis A, Hurt KC. PMID: 26432508.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    95. MET-Mutated NSCLC with Major Response to Crizotinib. J Thorac Oncol. 2015 May; 10(5):e33-e34. Mendenhall MA, Goldman JW. PMID: 25898965.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    96. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. PMID: 25923550.
      View in: PubMed   Mentions: 258     Fields:    Translation:HumansCTClinical Trials
    97. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21; 372(21):2018-28. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators. PMID: 25891174.
      View in: PubMed   Mentions: 2883     Fields:    Translation:HumansCTClinical Trials
    98. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. PMID: 25605849.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCellsCTClinical Trials
    99. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 01; 21(5):1002-9. Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, Ryan DP, Wirth LJ, Parikh A, Partyka J, Faessel H, Gangolli E, Stewart S, Rosen LS, Bowles DW. PMID: 25501576.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    100. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 01; 20(23):5918-26. Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS. PMID: 25261556; PMCID: PMC4570619.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    101. Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib. J Clin Oncol. 2014 Dec 01; 32(34):e114-6. Goldberg JM, Gavcovich T, Saigal G, Goldman JW, Rosen LS. PMID: 24550414; PMCID: PMC4876351.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    102. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013 Mar 25; 13:152. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS. PMID: 23530663; PMCID: PMC3626541.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    103. Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S377-8. Goldman JW, Garon EB. PMID: 23160324; PMCID: PMC3741037.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    104. Learning chronobiology by improving Wikipedia. J Biol Rhythms. 2012 Aug; 27(4):333-6. Chiang CD, Lewis CL, Wright MD, Agapova S, Akers B, Azad TD, Banerjee K, Carrera P, Chen A, Chen J, Chi X, Chiou J, Cooper J, Czurylo M, Downs C, Ebstein SY, Fahey PG, Goldman JW, Grieff A, Hsiung S, Hu R, Huang Y, Kapuria A, Li K, Marcu I, Moore SH, Moseley AC, Nauman N, Ness KM, Ngai DM, Panzer A, Peters P, Qin EY, Sadhu S, Sariol A, Schellhase A, Schoer MB, Steinberg M, Surick G, Tsai CA, Underwood K, Wang A, Wang MH, Wang VM, Westrich D, Yockey LJ, Zhang L, Herzog ED. PMID: 22855578.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    105. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 01; 118(23):5903-11. Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. PMID: 22605616.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    106. Intraocular involvement of mycosis fungoides. Arch Ophthalmol. 2009 Mar; 127(3):343-5. Ralli M, Goldman JW, Lee E, Pinter-Brown LC, Glasgow BJ, Sarraf D. PMID: 19273807.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Jonathan's Networks
    Concepts (262)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (65)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California